News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 23:00:00 29/07/2026 +03			5-day change	1st Jan Change
28.52 ^USD	-1.66%		-1.14%	-7.40%

07:56am	Nordic stocks in North America, Ericsson fell 1.7%	FW
07-24	Wall Street's Three-Front Squeeze

All News

Mentions Relevance

07-24	Stocks to Watch : Intel, Deckers, Edwards Lifesciences, Genmab	DJ
07-23	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	GL
07-23	Genmab A/S and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma	CI
07-22	TD Cowen Upgrades Genmab to Buy Rating, Boosts PT	MT
07-22	TD Cowen Upgrades Genmab to Buy From Hold, Raises Price Target to $43 From $32	MT
07-22	TD Cowen upgrades Genmab to buy (hold) - BN	FW
07-21	Goldman Sachs raises Genmab price target to 2,350 Danish kroner (2,300), reiterates buy - BN	FW
07-15	Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales	MT
07-15	Genmab's Darzalex sales totaled $4,207m in the second quarter	FW
07-15	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026	GL
07-07	Genmab Secures EU Approval for Drug Combination Intended for Relapsed or Refractory Follicular Lymphoma	MT
07-07	Genmab rebounds on a European Commission decision
07-07	EU approves expanded use of Genmab's Tepkinly	FW
07-07	Genmab Wins EU Approval for Follicular Lymphoma Treatment Combination	MT
07-06	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	GL
07-06	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	BU
07-06	Genmab Announces Tepkinly in Combination with Lenalidomide and Rituximab Is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
07-06	BNP Paribas raises the target price for Genmab to 2,500 Danish kroner (2,400), reiterates outperform - BN	FW
06-30	Genmab hit a Phase 3 endpoint with epcoritamab in lymphoma	FW
06-30	Genmab Says Epcoritamab Combo Improves Progression-free Survival in Phase 3 Blood Cancer Study	MT
06-30	Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial	MT
06-29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	BU
06-29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	GL
06-29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Demonstrating Statistically Significant Improvement in Progression-Free Survival	CI
06-24	AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs	MT